thymidine has been researched along with Liver Cirrhosis in 66 studies
Liver Cirrhosis: Liver disease in which the normal microcirculation, the gross vascular anatomy, and the hepatic architecture have been variably destroyed and altered with fibrous septa surrounding regenerated or regenerating parenchymal nodules.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The aim of this study was to assess whether prolonged telbivudine treatment improves liver inflammation and fibrosis." | 9.20 | Long-Term Telbivudine Treatment Results in Resolution of Liver Inflammation and Fibrosis in Patients with Chronic Hepatitis B. ( Bao, W; Chen, C; Dong, Y; Goodman, Z; Hou, JL; Jia, J; Naoumov, NV; Niu, J; Ren, H; Shi, G; Tan, D; Trylesinski, A; Wan, M; Wang, Q; Wang, Y; Wei, L; Xie, Q; Xu, D, 2015) |
| "There is limited data on the efficacy and outcome of telbivudine (LdT) therapy in patients with chronic hepatitis B and compensated cirrhosis." | 9.19 | Comparing the efficacy and clinical outcome of telbivudine and entecavir naïve patients with hepatitis B virus-related compensated cirrhosis. ( Chang, KC; Chen, CH; Chiu, KW; Hu, TH; Hung, CH; Lee, CM; Lin, MT; Tsai, MC; Tseng, PL; Yen, YH; Yu, HC, 2014) |
| "To study the therapeutic efficacy of 48-week telbivudine treatment on cirrhosis resulting from chronic hepatitis B." | 9.14 | [Telbivudine treatment on cirrhosis resulting from chronic hepatitis B]. ( Han, T; Liang, J; Xiao, SX, 2009) |
| " In this study, we reported a CHB patient with decompensated cirrhosis showing a significant improvement in massive proteinuria along with elevation of estimated glomerular filtration rate (eGFR) after 1 year treatment with telbivudine." | 7.85 | Improvement of telbivudine on renal function and massive proteinuria: A case report. ( Liu, J; Yao, N; Zhao, Y, 2017) |
| "Thirty-six HBeAg-positive patients with chronic hepatitis B (CHB) were enrolled for 52-week telbivudine monotherapy and were followed at treatment week (TW)-0, 4, 12, 24 and 52." | 7.81 | Telbivudine therapy may shape CD4(+) T-cell response to prevent liver fibrosis in patients with chronic hepatitis B. ( Jia, M; Jiang, W; Li, J; Li, L; Liu, Y; She, W; Wang, J, 2015) |
| "This study was aimed to evaluate the long-term effects of telbivudine (LdT) in the treatment of chronic hepatitis B (CHB) and HBV-related liver cirrhosis (LC) and to observe the changes of immunological responses during LdT treatment." | 7.81 | Efficacy of telbivudine in the treatment of chronic hepatitis b and liver cirrhosis and its effect on immunological responses. ( Gao, X; Liu, P; Lu, XD; Lu, YQ; Meng, N; Tang, WX; Wang, M; Yan, W; Zhang, SJ, 2015) |
| "Data are limited for comparison of the long-term efficacy of telbivudine (LdT) between hepatitis B virus (HBV)-related compensated and decompensated cirrhosis." | 7.80 | Comparison of telbivudine efficacy in treatment-naive patients with hepatitis B virus-related compensated and decompensated cirrhosis in 96 weeks. ( Li, J; Liu, J; Lu, W; Wang, J; Yang, X; Zhou, L, 2014) |
| "The aim of this study was to evaluate the efficacy and safety of telbivudine 600 mg/day compared with lamivudine 100 mg/day for 48 weeks of treatment in patients with hepatitis B-related cirrhosis." | 7.79 | Forty-eight-week retrospective study of telbivudine and lamivudine treatment in patients with hepatitis B-related cirrhosis. ( Chen, Y; Gao, Z; Han, Y; Han, Z; Jia, G; Li, C; Liu, J; Luo, G; Shi, Y; Xia, L; Yin, F; Zhou, X; Zhu, J, 2013) |
| " The aim of this study was to assess whether prolonged telbivudine treatment improves liver inflammation and fibrosis." | 5.20 | Long-Term Telbivudine Treatment Results in Resolution of Liver Inflammation and Fibrosis in Patients with Chronic Hepatitis B. ( Bao, W; Chen, C; Dong, Y; Goodman, Z; Hou, JL; Jia, J; Naoumov, NV; Niu, J; Ren, H; Shi, G; Tan, D; Trylesinski, A; Wan, M; Wang, Q; Wang, Y; Wei, L; Xie, Q; Xu, D, 2015) |
| "There is limited data on the efficacy and outcome of telbivudine (LdT) therapy in patients with chronic hepatitis B and compensated cirrhosis." | 5.19 | Comparing the efficacy and clinical outcome of telbivudine and entecavir naïve patients with hepatitis B virus-related compensated cirrhosis. ( Chang, KC; Chen, CH; Chiu, KW; Hu, TH; Hung, CH; Lee, CM; Lin, MT; Tsai, MC; Tseng, PL; Yen, YH; Yu, HC, 2014) |
| "To study the therapeutic efficacy of 48-week telbivudine treatment on cirrhosis resulting from chronic hepatitis B." | 5.14 | [Telbivudine treatment on cirrhosis resulting from chronic hepatitis B]. ( Han, T; Liang, J; Xiao, SX, 2009) |
| "The aim of this prospective study was to investigate the diagnostic value of ultrasound elastography for evaluating liver stiffness measurement (LSM) in 74 patients with hepatitis B virus (HBV) infection, treated with telbivudine (22 with chronic HBV infection, 32 with compensated cirrhosis and 20 with decompensated cirrhosis)." | 5.14 | The diagnostic value of ultrasound elastography in patients with hepatitis B virus infection: a prospective study. ( Bai, XF; Gou, YZ; Jiang, W; Liu, B; Yu, HT, 2010) |
| "Among the six drugs licensed for the treatment of chronic hepatitis B in the US, the preferred agents in 2008 will include entecavir, peginterferon alfa-2a, possibly telbivudine, and tenofovir following licensure." | 4.84 | Review article: current antiviral therapy of chronic hepatitis B. ( Ayoub, WS; Keeffe, EB, 2008) |
| " In this study, we reported a CHB patient with decompensated cirrhosis showing a significant improvement in massive proteinuria along with elevation of estimated glomerular filtration rate (eGFR) after 1 year treatment with telbivudine." | 3.85 | Improvement of telbivudine on renal function and massive proteinuria: A case report. ( Liu, J; Yao, N; Zhao, Y, 2017) |
| "A total of 546 consecutive cirrhotic patients treated with entecavir (n = 359), telbivudine (n = 104), or tenofovir (n = 83) for chronic hepatitis B were enrolled." | 3.85 | Long-term outcomes of hepatitis B virus-related cirrhosis treated with nucleos(t)ide analogs. ( Chen, CH; Hu, TH; Hung, CH; Lee, CM; Lu, SN; Tsai, MC; Wang, JH, 2017) |
| "Thirty-six HBeAg-positive patients with chronic hepatitis B (CHB) were enrolled for 52-week telbivudine monotherapy and were followed at treatment week (TW)-0, 4, 12, 24 and 52." | 3.81 | Telbivudine therapy may shape CD4(+) T-cell response to prevent liver fibrosis in patients with chronic hepatitis B. ( Jia, M; Jiang, W; Li, J; Li, L; Liu, Y; She, W; Wang, J, 2015) |
| "Entecavir (ETV) is effective in the treatment of chronic hepatitis B virus (HBV) infections, even in patients with underlying cirrhosis." | 3.81 | Efficacy of telbivudine compared with entecavir in hepatitis B virus-related cirrhosis: 2 year follow-up data. ( Byun, KS; Hyun, JJ; Kang, S; Kim, HR; Kim, JH; Kim, SY; Koo, JS; Lee, SW; Seo, YS; Suh, SJ; Um, SH; Yeon, JE; Yim, HJ, 2015) |
| "This study was aimed to evaluate the long-term effects of telbivudine (LdT) in the treatment of chronic hepatitis B (CHB) and HBV-related liver cirrhosis (LC) and to observe the changes of immunological responses during LdT treatment." | 3.81 | Efficacy of telbivudine in the treatment of chronic hepatitis b and liver cirrhosis and its effect on immunological responses. ( Gao, X; Liu, P; Lu, XD; Lu, YQ; Meng, N; Tang, WX; Wang, M; Yan, W; Zhang, SJ, 2015) |
| " To examine changes in phosphorylated Smad3 signalling before and after anti-HBV therapies, we chose 27 patients with chronic hepatitis B who underwent baseline and follow-up biopsies at 52 weeks from the start of nucleoside analogue treatments (Lamivudine 100 mg daily or Telbivudine 600 mg daily)." | 3.80 | Reversible phospho-Smad3 signalling between tumour suppression and fibrocarcinogenesis in chronic hepatitis B infection. ( Deng, YR; Jin, QL; Lian, ZX; Matsuzaki, K; Moritoki, Y; Murata, M; Niu, JQ; Tsuneyama, K; Yamaguchi, T; Yoshida, K, 2014) |
| "Data are limited for comparison of the long-term efficacy of telbivudine (LdT) between hepatitis B virus (HBV)-related compensated and decompensated cirrhosis." | 3.80 | Comparison of telbivudine efficacy in treatment-naive patients with hepatitis B virus-related compensated and decompensated cirrhosis in 96 weeks. ( Li, J; Liu, J; Lu, W; Wang, J; Yang, X; Zhou, L, 2014) |
| "Since the licensing of lamivudine in 1999, the treatment of chronic hepatitis B has been revolutionized by the introduction of oral nucleoside and nucleotide analogues (NAs), which act as inhibitors of the HBV polymerase." | 3.80 | Antiviral therapy of chronic hepatitis B. ( Berg, T; van Bömmel, F, 2014) |
| "The aim of this study was to evaluate the efficacy and safety of telbivudine 600 mg/day compared with lamivudine 100 mg/day for 48 weeks of treatment in patients with hepatitis B-related cirrhosis." | 3.79 | Forty-eight-week retrospective study of telbivudine and lamivudine treatment in patients with hepatitis B-related cirrhosis. ( Chen, Y; Gao, Z; Han, Y; Han, Z; Jia, G; Li, C; Liu, J; Luo, G; Shi, Y; Xia, L; Yin, F; Zhou, X; Zhu, J, 2013) |
| "The structure of the duodenum mucosa and proliferation of the epithelium were studied in 138 patients with chronic hepatitis and cirrhosis of the liver by count of the number of mitoses and that of cells labeled in the phase of DNA synthesis with 3H-thymidine." | 3.65 | [Proliferative properties of the epithelium of the duodenal mucosa in chronic hepatitis and liver cirrhosis]. ( Gerlovich, ESh; Iakhontova, OI; Kazaev, IS; Puzyrev, AA; Shul'man, VSh, 1977) |
| "Telbivudine treatment was an independent predictive factor for HBV DNA <300 copies/mL and ALT normalization (P = 0." | 2.77 | Randomized clinical trial: efficacy and safety of telbivudine and lamivudine in treatment-naïve patients with HBV-related decompensated cirrhosis. ( Avila, C; Bao, W; Chan, HL; Chen, YC; Choudhuri, G; Chutaputti, A; Gane, EJ; Hwang, SG; Piratvisuth, T; Prabhakar, B; Safadi, R; Sarin, SK; Suh, DJ; Tanwandee, T; Trylesinski, A; Yurdaydin, C, 2012) |
| "Hepatitis B is a major cause of hepatocellular carcinoma and liver cirrhosis." | 2.52 | Hepatitis B: encouraging the use of interferon. ( Krishnamoorthy, TL; Mutimer, D, 2015) |
| "Mortality and complications including hepatocellular carcinoma are associated primarily with cirrhosis and age, but not with HBeAg status or viral load probably because modern therapies considerably reduce viral replication in almost all patients." | 1.43 | Long-term follow-up of HBsAg-positive patients in Germany. ( Amani, A; Niederau, C; Thiel, A, 2016) |
| "Chronic hepatitis B affects 5-10% of HIV patients in Western countries." | 1.35 | Hepatitis B in HIV patients: what is the current treatment and what are the challenges? ( Barreiro, P; Fernández, JV; Labarga, P; Medrano, J; Soriano, V; Tuma, P; Vispo, E, 2009) |
| "In the present series of hepatocellular carcinoma patients, the 3-year clinical outcome was significantly affected by cell proliferation and ECM-associated antigens." | 1.29 | Biological markers in hepatocellular carcinoma: potential clinical implications. ( Costa, A; D'Errico, A; Faranda, A; Gennari, L; Grigioni, W; Regalia, E; Silvestrini, R, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 27 (40.91) | 18.7374 |
| 1990's | 2 (3.03) | 18.2507 |
| 2000's | 10 (15.15) | 29.6817 |
| 2010's | 27 (40.91) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Liang, X | 1 |
| Xie, Q | 2 |
| Tan, D | 2 |
| Ning, Q | 1 |
| Niu, J | 2 |
| Bai, X | 1 |
| Chen, S | 1 |
| Cheng, J | 1 |
| Yu, Y | 2 |
| Wang, H | 1 |
| Xu, M | 1 |
| Shi, G | 2 |
| Wan, M | 2 |
| Chen, X | 1 |
| Tang, H | 1 |
| Sheng, J | 1 |
| Dou, X | 1 |
| Shi, J | 1 |
| Ren, H | 2 |
| Wang, M | 2 |
| Zhang, H | 1 |
| Gao, Z | 2 |
| Chen, C | 2 |
| Ma, H | 1 |
| Chen, Y | 2 |
| Fan, R | 1 |
| Sun, J | 1 |
| Jia, J | 2 |
| Hou, J | 1 |
| Liu, J | 3 |
| Yao, N | 1 |
| Zhao, Y | 1 |
| Han, Z | 1 |
| Shi, Y | 1 |
| Zhu, J | 1 |
| Yin, F | 1 |
| Xia, L | 1 |
| Luo, G | 1 |
| Jia, G | 1 |
| Li, C | 1 |
| Zhou, X | 1 |
| Han, Y | 1 |
| Tian, Y | 1 |
| Ni, D | 1 |
| Yang, W | 1 |
| Zhang, Y | 1 |
| Zhao, K | 1 |
| Song, J | 1 |
| Mao, Q | 1 |
| Tian, Z | 1 |
| van Velkinburgh, JC | 1 |
| Yang, D | 1 |
| Wu, Y | 1 |
| Ni, B | 1 |
| Park, YH | 1 |
| Kim, BK | 1 |
| Kim, JK | 1 |
| Kim, HC | 1 |
| Kim, DY | 1 |
| Park, JY | 1 |
| Han, KH | 1 |
| Kim, SU | 1 |
| Shin, SH | 1 |
| Hahn, KY | 1 |
| Ahn, SH | 1 |
| Deng, YR | 1 |
| Yoshida, K | 2 |
| Jin, QL | 1 |
| Murata, M | 2 |
| Yamaguchi, T | 1 |
| Tsuneyama, K | 1 |
| Moritoki, Y | 1 |
| Niu, JQ | 1 |
| Matsuzaki, K | 2 |
| Lian, ZX | 1 |
| Calvaruso, V | 1 |
| Craxì, A | 1 |
| Yang, X | 1 |
| Li, J | 2 |
| Zhou, L | 1 |
| Wang, J | 3 |
| Lu, W | 1 |
| Tsai, MC | 2 |
| Yu, HC | 1 |
| Hung, CH | 2 |
| Lee, CM | 2 |
| Chiu, KW | 1 |
| Lin, MT | 1 |
| Tseng, PL | 1 |
| Chang, KC | 1 |
| Yen, YH | 1 |
| Chen, CH | 2 |
| Hu, TH | 2 |
| Jia, M | 1 |
| Liu, Y | 2 |
| She, W | 1 |
| Li, L | 1 |
| Jiang, W | 2 |
| Kim, HR | 1 |
| Yim, HJ | 1 |
| Kang, S | 1 |
| Suh, SJ | 1 |
| Kim, SY | 1 |
| Hyun, JJ | 1 |
| Koo, JS | 1 |
| Kim, JH | 1 |
| Seo, YS | 1 |
| Yeon, JE | 1 |
| Lee, SW | 1 |
| Byun, KS | 1 |
| Um, SH | 1 |
| van Bömmel, F | 1 |
| Berg, T | 1 |
| Coffin, CS | 1 |
| Rezaeeaval, M | 1 |
| Pang, JX | 1 |
| Alcantara, L | 1 |
| Klein, P | 1 |
| Burak, KW | 1 |
| Myers, RP | 1 |
| Cholongitas, E | 1 |
| Vasiliadis, T | 1 |
| Goulis, I | 1 |
| Fouzas, I | 1 |
| Antoniadis, N | 1 |
| Papanikolaou, V | 1 |
| Akriviadis, E | 1 |
| Meng, N | 1 |
| Gao, X | 1 |
| Yan, W | 1 |
| Liu, P | 1 |
| Lu, XD | 1 |
| Zhang, SJ | 1 |
| Lu, YQ | 1 |
| Tang, WX | 1 |
| Hou, JL | 2 |
| Xu, D | 1 |
| Goodman, Z | 1 |
| Wei, L | 1 |
| Wang, Q | 1 |
| Wang, Y | 1 |
| Bao, W | 2 |
| Dong, Y | 1 |
| Trylesinski, A | 2 |
| Naoumov, NV | 1 |
| Krishnamoorthy, TL | 1 |
| Mutimer, D | 1 |
| Niederau, C | 2 |
| Amani, A | 1 |
| Thiel, A | 1 |
| Wang, GL | 1 |
| Qiu, P | 1 |
| Zhou, SF | 1 |
| Xu, LF | 1 |
| Wen, P | 1 |
| Wen, JB | 1 |
| Xiao, XZ | 1 |
| Yue-Meng, W | 1 |
| Li, YH | 1 |
| Wu, HM | 1 |
| Yang, J | 1 |
| Xu, Y | 1 |
| Yang, LH | 1 |
| Yang, JH | 1 |
| Lu, SN | 1 |
| Wang, JH | 1 |
| Shen, H | 1 |
| Ding, F | 1 |
| Wang, Z | 1 |
| Sun, F | 1 |
| Zhou, J | 1 |
| Xu, W | 1 |
| Ni, J | 1 |
| Yang, Y | 1 |
| Chien, RN | 1 |
| Liaw, YF | 1 |
| Liang, J | 1 |
| Han, T | 1 |
| Xiao, SX | 1 |
| Chen, W | 1 |
| Soriano, V | 1 |
| Tuma, P | 1 |
| Vispo, E | 1 |
| Labarga, P | 1 |
| Fernández, JV | 1 |
| Medrano, J | 1 |
| Barreiro, P | 1 |
| Gou, YZ | 1 |
| Liu, B | 1 |
| Yu, HT | 1 |
| Bai, XF | 1 |
| Cho, YK | 1 |
| Song, BC | 1 |
| Singal, AK | 1 |
| Fontana, RJ | 1 |
| Chan, HL | 1 |
| Chen, YC | 1 |
| Gane, EJ | 1 |
| Sarin, SK | 1 |
| Suh, DJ | 1 |
| Piratvisuth, T | 1 |
| Prabhakar, B | 1 |
| Hwang, SG | 1 |
| Choudhuri, G | 1 |
| Safadi, R | 1 |
| Tanwandee, T | 1 |
| Chutaputti, A | 1 |
| Yurdaydin, C | 1 |
| Avila, C | 1 |
| Huang, Y | 1 |
| Wu, H | 1 |
| Wu, S | 1 |
| Fu, D | 1 |
| Ma, Y | 1 |
| Shen, X | 1 |
| MACDONALD, RA | 3 |
| MALLORY, GK | 2 |
| LEEVY, CM | 3 |
| TENHOVE, W | 1 |
| HOWARD, M | 1 |
| RAMALINGASWAMI, V | 1 |
| SCHMID, R | 1 |
| Hrckova, G | 1 |
| Velebný, S | 1 |
| Daxnerová, Z | 1 |
| Solár, P | 1 |
| Sekimoto, G | 1 |
| Uemura, Y | 1 |
| Sakaida, N | 1 |
| Kaibori, M | 1 |
| Kamiyama, Y | 1 |
| Nishizawa, M | 1 |
| Fujisawa, J | 1 |
| Okazaki, K | 1 |
| Seki, T | 1 |
| Ayoub, WS | 1 |
| Keeffe, EB | 1 |
| Winter, GC | 1 |
| McCarthy, CF | 1 |
| Read, AE | 1 |
| Yoffey, JM | 1 |
| Gimferrer, E | 1 |
| Guarner, C | 1 |
| Balanzó, J | 1 |
| Ayats, R | 1 |
| Fábrega, J | 1 |
| Baiget, M | 1 |
| Pujol, N | 1 |
| Presa, F | 1 |
| Simón, X | 1 |
| Altés, R | 1 |
| Silvestrini, R | 1 |
| Costa, A | 1 |
| D'Errico, A | 1 |
| Faranda, A | 1 |
| Regalia, E | 1 |
| Grigioni, W | 1 |
| Gennari, L | 1 |
| Wang, JY | 1 |
| Zhang, QS | 1 |
| Guo, JS | 1 |
| Hu, MY | 1 |
| Zolotnitskaia, RP | 1 |
| Sorokin, AV | 1 |
| Boss, JH | 1 |
| Okon, E | 1 |
| Rosenmann, E | 1 |
| Barinsky, IF | 1 |
| Dementiev, IV | 1 |
| Shvetsova, TP | 1 |
| Ugryumov, EP | 1 |
| Ryabova, MV | 1 |
| Bugbee, SJ | 1 |
| Sutnick, AI | 1 |
| Millman, I | 1 |
| Blumberg, BS | 1 |
| Gerlovich, ESh | 1 |
| Iakhontova, OI | 1 |
| Puzyrev, AA | 1 |
| Shul'man, VSh | 1 |
| Kazaev, IS | 1 |
| Griffith, DP | 1 |
| Musher, DM | 1 |
| Lanfrancone, L | 1 |
| Boraschi, D | 1 |
| Ghiara, P | 1 |
| Falini, B | 1 |
| Grignani, F | 1 |
| Peri, G | 1 |
| Mantovani, A | 1 |
| Pelicci, PG | 1 |
| Tsuji, T | 1 |
| Nozaki, H | 1 |
| Naito, K | 1 |
| Kosaka, K | 1 |
| Pappas, A | 1 |
| Phlippen, R | 1 |
| Pütz, T | 1 |
| Scheurlen, PG | 1 |
| Mohr, U | 1 |
| Speetzen, R | 1 |
| Knecht, M | 1 |
| Wrba, H | 1 |
| Maerker-Alzer, G | 1 |
| Schumacher, K | 1 |
| Gross, R | 1 |
| Berenyi, MR | 1 |
| Straus, B | 1 |
| Cruz, D | 1 |
| Sorrell, MF | 1 |
| Scheiffarth, F | 1 |
| Warnatz, H | 1 |
| Ottenjann, R | 1 |
| Ritter, H | 1 |
| Stöcker, E | 1 |
| Heine, WD | 1 |
| Surianu, P | 1 |
| Heiniger, HJ | 1 |
| Feinendegen, LE | 1 |
| Okura, T | 1 |
| Rubin, E | 1 |
| Hutterer, F | 1 |
| Popper, H | 1 |
| Newberne, PM | 1 |
| Rogers, AE | 1 |
| Bailey, C | 1 |
| Young, VR | 1 |
| Shea, SM | 2 |
| Bartholomay, AF | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Single Arm, Multicenter, Open-label, 52-week, the Omnibus Extension Study to Evaluate the Safety and Efficacy of Telbivudine in the Fifth Year of Treatment in Chinese Patients With Compensated Chronic Hepatitis B and Are HBV DNA PCR Negative at the End [NCT00646503] | Phase 4 | 150 participants (Actual) | Interventional | 2008-03-31 | Completed | ||
| A Single-arm, Multicenter, Open-label, 52-week Treatment, Extension Study to CLDT600ACN04 Study to Evaluate the Efficacy (Including Histological Improvement) and Safety in Fourth to Sixth Year of Telbivudine Treatment in Patients With Chronic Hepatitis B[NCT00877149] | Phase 4 | 80 participants (Anticipated) | Interventional | 2009-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
7 reviews available for thymidine and Liver Cirrhosis
| Article | Year |
|---|---|
Regression of fibrosis after HBV antiviral therapy. Is cirrhosis reversible?
Topics: Adenine; Administration, Oral; Antiviral Agents; Carcinoma, Hepatocellular; Fibrosis; Guanine; Hepat | 2014 |
Hepatitis B: encouraging the use of interferon.
Topics: Adjuvants, Immunologic; Antiviral Agents; Carcinoma, Hepatocellular; Contraindications; Drug Adminis | 2015 |
Nucleos(t)ide analogues for hepatitis B virus: strategies for long-term success.
Topics: Adenine; Adenine Nucleotides; Alanine Transaminase; Carcinoma, Hepatocellular; DNA, Viral; Drug Admi | 2008 |
Meta-analysis: oral anti-viral agents in adults with decompensated hepatitis B virus cirrhosis.
Topics: Adenine; Administration, Oral; Adult; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combin | 2012 |
A meta-analysis of nucleos(t)ide analogues in patients with decompensated cirrhosis due to hepatitis B.
Topics: Antiviral Agents; Hepatitis B; Humans; Lamivudine; Liver Cirrhosis; Nucleosides; Nucleotides; Revers | 2013 |
Review article: current antiviral therapy of chronic hepatitis B.
Topics: Adenine; Antiviral Agents; Carcinoma, Hepatocellular; Deoxycytidine; Drug Resistance, Viral; Emtrici | 2008 |
[Lymphocyte transformation in liver diseases (review of the literature)].
Topics: Antigens; Chronic Disease; Glucocorticoids; Hepatitis; Humans; Liver; Liver Cirrhosis; Liver Disease | 1975 |
8 trials available for thymidine and Liver Cirrhosis
| Article | Year |
|---|---|
Interpretation of liver stiffness measurement-based approach for the monitoring of hepatitis B patients with antiviral therapy: A 2-year prospective study.
Topics: Adolescent; Adult; Alanine Transaminase; Antiviral Agents; Biopsy; Drug Monitoring; Drug Therapy, Co | 2018 |
Comparing the efficacy and clinical outcome of telbivudine and entecavir naïve patients with hepatitis B virus-related compensated cirrhosis.
Topics: Adult; Aged; Alanine Transaminase; Antiviral Agents; Disease Progression; DNA, Viral; Female; Guanin | 2014 |
Long-Term Telbivudine Treatment Results in Resolution of Liver Inflammation and Fibrosis in Patients with Chronic Hepatitis B.
Topics: Adult; Antiviral Agents; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hu | 2015 |
Long-Term Telbivudine Treatment Results in Resolution of Liver Inflammation and Fibrosis in Patients with Chronic Hepatitis B.
Topics: Adult; Antiviral Agents; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hu | 2015 |
Long-Term Telbivudine Treatment Results in Resolution of Liver Inflammation and Fibrosis in Patients with Chronic Hepatitis B.
Topics: Adult; Antiviral Agents; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hu | 2015 |
Long-Term Telbivudine Treatment Results in Resolution of Liver Inflammation and Fibrosis in Patients with Chronic Hepatitis B.
Topics: Adult; Antiviral Agents; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hu | 2015 |
Cost-effectiveness of Lamivudine, Telbivudine, Adefovir Dipivoxil and Entecavir on decompensated hepatitis B virus-related cirrhosis.
Topics: Adenine; Adult; Antiviral Agents; Cost-Benefit Analysis; Female; Guanine; Hepatitis B virus; Hepatit | 2016 |
Comparison of Telbivudine and Entecavir Therapy on Nephritic Function and Drug Resistance in Patients with Hepatitis B Virus-Related Compensated Cirrhosis.
Topics: Creatinine; DNA, Viral; Drug Resistance, Viral; Female; Glomerular Filtration Rate; Guanine; Hepatit | 2016 |
[Telbivudine treatment on cirrhosis resulting from chronic hepatitis B].
Topics: Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female; Hepatitis B e Antigens; Hepatit | 2009 |
The diagnostic value of ultrasound elastography in patients with hepatitis B virus infection: a prospective study.
Topics: Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; Asian People; China; Demography; El | 2010 |
Randomized clinical trial: efficacy and safety of telbivudine and lamivudine in treatment-naïve patients with HBV-related decompensated cirrhosis.
Topics: Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Double-Blind Method; Fe | 2012 |
51 other studies available for thymidine and Liver Cirrhosis
| Article | Year |
|---|---|
Improvement of telbivudine on renal function and massive proteinuria: A case report.
Topics: Antiviral Agents; Biomarkers; Hepatitis B, Chronic; Humans; Kidney Function Tests; Liver Cirrhosis; | 2017 |
Forty-eight-week retrospective study of telbivudine and lamivudine treatment in patients with hepatitis B-related cirrhosis.
Topics: Adolescent; Adult; Aged; Antiviral Agents; DNA, Viral; Female; Hepatitis B; Hepatitis B e Antigens; | 2013 |
Telbivudine treatment corrects HBV-induced epigenetic alterations in liver cells of patients with chronic hepatitis B.
Topics: Antiviral Agents; Case-Control Studies; Chromatin; Enhancer of Zeste Homolog 2 Protein; Epigenesis, | 2014 |
Long-term outcomes of chronic hepatitis B virus infection in the era of antiviral therapy in Korea.
Topics: Adult; Age Factors; Antiviral Agents; Carcinoma, Hepatocellular; Disease Progression; Female; Follow | 2014 |
Reversible phospho-Smad3 signalling between tumour suppression and fibrocarcinogenesis in chronic hepatitis B infection.
Topics: Adult; Antiviral Agents; Carcinoma, Hepatocellular; Disease Progression; DNA, Viral; Female; Hepatit | 2014 |
Comparison of telbivudine efficacy in treatment-naive patients with hepatitis B virus-related compensated and decompensated cirrhosis in 96 weeks.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Biomarkers; Cholinesterases; Drug Resistance, Viral; | 2014 |
Telbivudine therapy may shape CD4(+) T-cell response to prevent liver fibrosis in patients with chronic hepatitis B.
Topics: Adolescent; Adult; Antiviral Agents; Case-Control Studies; CD4-Positive T-Lymphocytes; Cells, Cultur | 2015 |
Efficacy of telbivudine compared with entecavir in hepatitis B virus-related cirrhosis: 2 year follow-up data.
Topics: Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug-Related Side Effects and Adverse R | 2015 |
Antiviral therapy of chronic hepatitis B.
Topics: Adenine; Antiviral Agents; Arabinofuranosyluracil; Carcinoma, Hepatocellular; Gene Products, pol; Gu | 2014 |
The incidence of hepatocellular carcinoma is reduced in patients with chronic hepatitis B on long-term nucleos(t)ide analogue therapy.
Topics: Adenine; Adult; Antiviral Agents; Canada; Carcinoma, Hepatocellular; Female; Guanine; Hepatitis B e | 2014 |
Telbivudine is associated with improvement of renal function in patients transplanted for HBV liver disease.
Topics: Adult; Aged; Antiviral Agents; Chemoprevention; DNA, Viral; Female; Glomerular Filtration Rate; Hepa | 2015 |
Efficacy of telbivudine in the treatment of chronic hepatitis b and liver cirrhosis and its effect on immunological responses.
Topics: Adult; Aged; Antiviral Agents; Female; Hepatitis B, Chronic; Humans; Liver Cirrhosis; Male; Middle A | 2015 |
Long-term follow-up of HBsAg-positive patients in Germany.
Topics: Adenine; Adult; Age Factors; Antiviral Agents; Carcinoma, Hepatocellular; DNA, Viral; Drug Therapy, | 2016 |
Telbivudine versus lamivudine and entecavir for treatment-naïve decompensated hepatitis B virus-related cirrhosis.
Topics: Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Drug-Related Side Effects and Adver | 2017 |
Long-term outcomes of hepatitis B virus-related cirrhosis treated with nucleos(t)ide analogs.
Topics: Adult; Aged; Antiviral Agents; Carcinoma, Hepatocellular; Female; Guanine; Hepatitis B, Chronic; Hum | 2017 |
[Pharmacoeconomic evaluation of telbivudine vs. lamivudine in treating the patients with HBeAg-positive and negative chronic hepatitis B].
Topics: Adult; Antifungal Agents; China; Cost-Benefit Analysis; DNA, Viral; Drug Costs; Economics, Pharmaceu | 2009 |
Hepatitis B in HIV patients: what is the current treatment and what are the challenges?
Topics: Adenine; Antiviral Agents; Deoxycytidine; DNA, Viral; Drug Therapy, Combination; Emtricitabine; Guan | 2009 |
[New insight for HBV DNA and HBsAg quantitation during antiviral therapy in patients with chronic hepatitis B].
Topics: Antiviral Agents; Carcinoma, Hepatocellular; DNA, Viral; Hepatitis B Surface Antigens; Hepatitis B v | 2011 |
Fibrous tissue in nutritional cirrhosis; autoradiographic studies with use of tritiated thymidine.
Topics: Autoradiography; Humans; Liver Cirrhosis; Lymphatic Vessels; Thymidine | 1959 |
"Lifespan" of liver cells. Autoradio-graphic study using tritiated thymidine in normal, cirrhotic, and partially hepatectomized rats.
Topics: Animals; Liver; Liver Cirrhosis; Nucleosides; Nucleotides; Rats; Thymidine | 1961 |
MESENCHYMAL-CELL PROLIFERATION IN LIVER DISEASE OF THE ALCOHOLIC.
Topics: Alcoholism; Autoradiography; Cell Proliferation; DNA; Ethanol; Fatty Liver; Liver; Liver Cirrhosis; | 1964 |
PERSPECTIVES IN PROTEIN MALNUTRITION.
Topics: Animals; Fatty Liver; Haplorhini; Jejunum; Kwashiorkor; Liver Cirrhosis; Pancreas; Pathology; Protei | 1964 |
HEPATIC DNA SYNTHESIS AND REGENERATION.
Topics: Adrenal Cortex Hormones; Anabolic Agents; Autoradiography; Biopsy; Diet; Diet Therapy; DNA; Drug The | 1964 |
Regeneration in fatty liver and cirrhosis: autoradiographic study using tritiated thymidine.
Topics: Animals; Fatty Liver; Liver Cirrhosis; Liver Cirrhosis, Experimental; Liver Diseases; Nucleosides; N | 1960 |
Praziquantel and liposomized glucan-treatment modulated liver fibrogenesis and mastocytosis in mice infected with Mesocestoides vogae (M. corti, Cestoda) tetrathyridia.
Topics: Animals; Anthelmintics; beta-Glucans; Bromodeoxyuridine; Cestode Infections; Collagen; Drug Therapy, | 2006 |
Chronic inflammation associated with hepatitis C virus infection perturbs hepatic transforming growth factor beta signaling, promoting cirrhosis and hepatocellular carcinoma.
Topics: alpha-Fetoproteins; Biopsy; Carcinoma, Hepatocellular; Disease Progression; DNA Replication; Hepatit | 2007 |
[Treatment in every detected virus replication. New guideline for therapy of hepatitis B publicized].
Topics: Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Hepatitis B virus; Hepatitis B, Chronic; Human | 2007 |
[New German and American guidelines for therapy of hepatitis B. Discrepancies and similarities].
Topics: Adenine; Alanine Transaminase; Antiviral Agents; Biopsy; DNA, Viral; Drug Resistance, Viral; Drug Th | 2007 |
Development of macrophages in phytohaemagglutinin cultures of blood from patients with idiopathic steatorrhoea and with cirrhosis.
Topics: Adolescent; Adult; Aged; Autoradiography; Celiac Disease; Culture Media; DNA; Female; Hemagglutinati | 1967 |
[Macrocytosis in the liver patient: study of blood folate and vitamin B 12, and thymidine synthesis in hematopoietic cells].
Topics: Adult; Anemia, Macrocytic; Anemia, Megaloblastic; Female; Folic Acid; Hematopoietic Stem Cells; Huma | 1982 |
Biological markers in hepatocellular carcinoma: potential clinical implications.
Topics: Antigens, Neoplasm; Biomarkers; Carcinoma, Hepatocellular; Cell Cycle; Cell Division; Collagenases; | 1993 |
Effects of glycyrrhetinic acid on collagen metabolism of hepatic stellate cells at different stages of liver fibrosis in rats.
Topics: Administration, Topical; Animals; Anti-Inflammatory Agents; Carbon Tetrachloride; Cell Division; Col | 2001 |
alpha-fetoprotein in rats treated with anti-thymocytic serum.
Topics: alpha-Fetoproteins; Animals; Antilymphocyte Serum; Diet; Female; Glomerulonephritis; Liver; Liver Ci | 1977 |
Investigation of the nature of Australia antigen. I: The absence of biological activity of Australia antigen in human blood leukocyte culture.
Topics: Adolescent; Adult; Chromosome Aberrations; DNA Nucleotidyltransferases; Down Syndrome; Female; Hepat | 1975 |
[Proliferative properties of the epithelium of the duodenal mucosa in chronic hepatitis and liver cirrhosis].
Topics: Adult; Autoradiography; Cell Count; Cell Division; Chronic Disease; DNA; Duodenum; Epithelium; Hepat | 1977 |
Acetohydroxamic acid. Potential use in urinary infection caused by urea-splitting bacteria.
Topics: Acetamides; Administration, Oral; Animals; Bacteria; Binding Sites; Chemical Phenomena; Chemistry; D | 1975 |
Human peritoneal mesothelial cells produce many cytokines (granulocyte colony-stimulating factor [CSF], granulocyte-monocyte-CSF, macrophage-CSF, interleukin-1 [IL-1], and IL-6) and are activated and stimulated to grow by IL-1.
Topics: Antigens, CD; Blotting, Northern; Cell Division; Cells, Cultured; Cytokines; DNA; Epithelium; Granul | 1992 |
Blast-like transformation of lymphocyte stimulated with Australia antigen--brief note.
Topics: Abdomen; Adult; Aged; Autoradiography; Chronic Disease; Female; Hepatitis; Hepatitis B Antigens; Hum | 1972 |
[Disturbance of the cellular immunoreaction at the initial stage of acute infectious hepatitis].
Topics: Carbon Isotopes; Cell Count; Culture Techniques; DNA, Bacterial; Hepatitis A; Hepatovirus; Humans; H | 1970 |
[Regeneration, following partial hepatectomy, of liver chronically damaged by diethylnitrosamine].
Topics: Animals; Autoradiography; DNA; Female; Hepatectomy; Liver; Liver Cirrhosis; Liver Regeneration; Nitr | 1968 |
Detection of lymphocytes with increased DNA-synthesis in the peripheral blood of patients with active chronic hepatitis.
Topics: Antibodies; Antibodies, Antinuclear; Blood Donors; Chronic Disease; DNA; Hepatitis; Hepatitis B Anti | 1974 |
In vitro and in vivo studies of cellular immunity in alcoholic cirrhosis.
Topics: Alcoholism; Candida albicans; Carbon Radioisotopes; Chlorine; Croton Oil; Humans; Hypersensitivity, | 1974 |
Lymphocyte transformation and alcoholic liver injury.
Topics: Acetaldehyde; Alcoholism; Cells, Cultured; Chemical and Drug Induced Liver Injury; DNA; Ethanol; Fat | 1972 |
[Lymphocyte transformation in chronic hepatitis and other hepatic diseases].
Topics: Antibodies; Autoradiography; Chronic Disease; Culture Techniques; Fatty Liver; Fluorescent Antibody | 1969 |
Regeneration of liver parenchyma under normal and pathological conditions.
Topics: Acetamides; Age Factors; Animals; Autoradiography; Cell Division; Epithelium; Hepatectomy; Liver; Li | 1971 |
[Diminished phytohemagglutinin stimulation of human lymphocyte cultures in liver cirrhosis: studies with 3H-thymidine and I-125 desoxyuridine].
Topics: Culture Techniques; Deoxyuridine; DNA; Hepatitis; Humans; Iodine Radioisotopes; Lectins; Liver; Live | 1970 |
Study on the pathogenesis of nephritis (with special reference to autoradiography). I. Experimental studies.
Topics: Animals; Autoradiography; Carbon Tetrachloride Poisoning; DNA; Kidney Glomerulus; Kidney Tubules; Li | 1970 |
Experimental hepatic fibrosis without hepatocellular regeneration. A kinetic study.
Topics: Animals; Antibodies, Heterophile; Autoradiography; Body Weight; Collagen; DNA; Humans; Immune Sera; | 1968 |
The induction of liver cirrhosis in rats by purified amino acid diets.
Topics: Amino Acids; Animals; Body Weight; Cholesterol; Choline Deficiency; Deficiency Diseases; Diet; Dieta | 1969 |
In numero studies in a cell renewal system. Periodically adjusted cell renewal process.
Topics: Animals; Autoradiography; Carbon Tetrachloride; Computers; DNA; Kinetics; Liver Cirrhosis; Liver Cir | 1965 |
Experimental toxic cirrhosis in the rat. Kinetics of hepatocyte proliferation during intermittent carbon tetrachloride intoxication.
Topics: Animals; Autoradiography; Biometry; Carbon Tetrachloride Poisoning; Cell Division; Computers; Kineti | 1966 |